Table 4.
Comparison of current study with other reports on first-line chemotherapy regimens for metastatic ESCC
| Regimen | N | ORR (%) | PFS/TTP (months) | OS (months) | Author |
|---|---|---|---|---|---|
| Nab-PTX+DDP | 33 | 60.6 | 6.2 | 15.5 | Current study |
| PTX+CAP | |||||
| 1st line | 12 | 75.0 | 5.23 | 14.3 | Yun et al26 |
| 2nd line | 20 | 45.0 | 4.54 | 8.4 | |
| CAP+DDP | 72 | 51.4 | 4.2 | 12.0 | Lee et al32 |
| TXT+DDP+5-Fu | 39 | 66.6 | 7.0 | 13.0 | Takahashi et al27 |
| ADM+5-Fu+DDP | 41 | 43.9 | NR | 10.2 | Honda et al33 |
| PTX+NDP (ESCC = 46) | 48 | 41.7 | 6.1 | 11.5 | Cao et al28 |
| PTX+NDP (ESCC = 33) | 36 | 43.6 | 6.1 | 10.3 | Gong et al29 |
| 5-Fu+DDP | 32 | 13.0 | 3.6 | 5.5 | Lorenzen et al34 |
| 5-Fu+DDP+cetuximab | 32 | 19.0 | 5.9 | 9.5 | |
| OXA+CAP | 64 | 43.8 | 4.0 | 10.0 | Qin et al35 |
| CAP+DDP | 45 | 57.8 | 4.7 | 11.2 | Lee et al36 |
| PTX+DDP | 35 | 48.6 | 7.0 | 13.0 | Zhang et al30 |
| TXT+DDP | |||||
| ESCC | 10 | 40.0 | 4.3 | 6.9 | Laack et al31 |
| EADC | 6 | 20.0 |
Abbreviations: 5-Fu, 5-fluorouracil; ADM, doxorubicin; CAP, capecitabine; DCR, disease control rate; DDP, cisplatin; EADC, esophageal adenocarcinoma; ESCC, esophageal squamous cell carcinoma; N, number; Nab-PTX, nanoparticle albumin-bound paclitaxel; NDP, nedaplatin; NR, not reported; ORR, objective response rate; OS, overall survival; OXA, oxaliplatin; PFS, progression-free survival; TTP, time to progression; TXT, docetaxel; PTX, paclitaxel.